Thromboreductin Uses

Rating: 2.5 - 2 review(s)
What is the dose of your medication?

What is Thromboreductin?

Thromboreductin lowers the number of blood clotting cells (platelets) in the body, which helps prevent blood clots from forming.

Thromboreductin is used to treat a condition called thrombocythemia (also called thrombocytosis). Thrombocythemia is a blood cell disorder in which too many platelet cells are produced, causing bleeding or blood-clotting problems.

Thromboreductin may also be used for purposes not listed in this medication guide.

Thromboreductin indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.

Thromboreductin is a medicine which interferes with the development of platelets. It reduces the number of platelets produced by the bone marrow, which results in a decrease in the platelet count in the blood towards a more normal level. For this reason it is used to treat patients with essential thrombocythaemia.

Essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of the blood cells known as platelets. Large numbers of platelets in the blood can cause serious problems with blood circulation and clotting.

How should I use Thromboreductin?

Use Thromboreductin as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Take Thromboreductin by mouth with or without food.
  • Take Thromboreductin on a regular schedule to get the most benefit from it. It may take several weeks (4 to 12 weeks) before you get the full effect from Thromboreductin.
  • If you miss a dose of Thromboreductin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Thromboreductin.

Uses of Thromboreductin in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Use: Labeled Indications

Essential thrombocythemia: Treatment of thrombocythemia secondary to myeloproliferative neoplasms to reduce elevated platelets and the risk of thrombosis and to reduce associated symptoms (including thrombo-hemorrhagic events).

Note: The use of hydroxyurea and low-dose aspirin may be preferred over Thromboreductin for the initial treatment of essential thrombocythemia; however, Thromboreductin may be appropriate in patients who are resistant or intolerant to hydroxyurea (ESMO [Vannucchi 2015]).

Thromboreductin description

Thromboreductin is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. [Wikipedia]

Thromboreductin dosage

Starting Dose


The recommended starting dosage of Thromboreductin is 0.5 mg four times daily or 1 mg twice daily.

Pediatric Patients

The recommended starting dosage of Thromboreductin is 0.5 mg daily.


Continue the starting dose for at least one week and then titrate to reduce and maintain the platelet count below 600,000/μL, and ideally between 150,000/μL and 400,000/μL. The dose increment should not exceed 0.5 mg/day in any one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose. Most patients will experience an adequate response at a dose of 1.5 to 3.0 mg/day. Monitor platelet counts weekly during titration then monthly or as necessary.

Dose Modifications For Hepatic Impairment

In patients with moderate hepatic impairment (Child Pugh score 7-9) start Thromboreductin therapy at a dose of 0.5 mg/day and monitor frequently for cardiovascular events. Patients with moderate hepatic impairment who have tolerated Thromboreductin therapy for one week may have their dose increased. The dose increase increment should not exceed 0.5 mg/day in any one week. Avoid use of Thromboreductin in patients with severe hepatic impairment.

Clinical Monitoring

Thromboreductin therapy requires clinical monitoring, including complete blood counts, assessment of hepatic and renal function, and electrolytes.

To prevent the occurrence of thrombocytopenia, monitor platelet counts every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached. Typically, platelet counts begin to respond within 7 to 14 days at the proper dosage. In the clinical trials, the time to complete response, defined as platelet count ≤ 600,000/μL, ranged from 4 to 12 weeks. In the event of dosage interruption or treatment withdrawal, the rebound in platelet count is variable, but platelet counts typically will start to rise within 4 days and return to baseline levels in one to two weeks, possibly rebounding above baseline values. Monitor platelet counts frequently.

How supplied

Dosage Forms And Strengths

White, opaque capsule, containing 0.5 mg Thromboreductin (as Thromboreductin), imprinted with “063” in black ink.

Storage And Handling

Thromboreductin is available as 0.5 mg, opaque, white capsules imprinted “063” in black ink: NDC 54092-063-01 = bottle of 100

Store at 25°C (77°F) excursions permitted to 15-30°C (59-86°F),. Store in a light resistant container.

Manufactured for Shire US Inc., 725 Chesterbrook Blvd., Wayne, PA 19087, USA. 1-800-828-2088. Revised: July 2015.

Thromboreductin interactions

See also:
What other drugs will affect Thromboreductin?


Limited PK and/or PD studies investigating possible interactions between Thromboreductin and other medicinal products have been conducted. In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of Thromboreductin, nor does Thromboreductin affect the PK properties of digoxin or warfarin.

Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with Thromboreductin in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol. There is no clinical evidence to suggest that Thromboreductin interacts with any of these compounds.

An in vivo interaction study in humans demonstrated that a single 1mg dose of Thromboreductin administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated. There was no effect on bleeding time, PT or aPTT. No clinically relevant pharmacokinetic interactions between Thromboreductin and acetylsalicylic acid were observed. In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo. Thromboreductin alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.

Thromboreductin is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of Thromboreductin. Thromboreductin demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.

Thromboreductin is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by Thromboreductin.

There is a single case report, which suggests that sucralfate may interfere with Thromboreductin absorption.

Food has no clinically significant effect on the bioavailability of Thromboreductin.

Thromboreductin side effects

See also:
What are the possible side effects of Thromboreductin?


Analysis of the adverse events in a population consisting of 942 patients in 3 clinical studies diagnosed with myeloproliferative diseases of varying etiology (ET: 551; PV: 117; OMPD: 274) has shown that all disease groups have the same adverse event profile. While most reported adverse events during Thromboreductin therapy have been mild in intensity and have decreased in frequency with continued therapy, serious adverse events were reported in these patients. These include the following: congestive heart failure, myocardial infarction, cardiomyopathy, cardiomegaly, complete heart block, atriala fibrillation, cerebrovascular accident, pericarditis, pericardial effusion, pleural effusion, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, and seizure.

Of the 942 patients treated with Thromboreductin for a mean duration of approximately 65 weeks, 161 (17%) were discontinued from the study because of adverse events or abnormal laboratory test results. The most common adverse events for treatment discontinuation were headache, diarrhea, edema, palpitations, and abdominal pain. Overall, the occurrence rate of all adverse events was 17.9 per 1,000 treatment days. The occurrence rate of adverse events increased at higher dosages of Thromboreductin. The most frequently reported adverse reactions to Thromboreductin (in 5% or greater of 942 patients with myeloproliferative disease) in clinical trials were:





Edema, other..........................20.6%


Abdominal Pain.....................16.4%


Pain, other..............................15.0%





Peripheral Edema...................8.5%

Rash, including urticaria........8.3%

Chest Pain..............................7.8%







Back Pain...............................5.9%



Adverse events with an incidence of 1% to < 5% included:

Body as a Whole System: Flu symptoms, chills, photosensitivity.

Cardiovascular System: Arrhythmia, hemorrhage, hypertension, cardiovascular disease, angina pectoris, heart failure, postural hypotension, thrombosis, vasodilatation, migraine, syncope.

Digestive System: Constipation, GI distress, GI hemorrhage, gastritis, melena, aphthous stomatitis, eructation.

Hemic & Lymphatic System: Anemia, thrombocytopenia, ecchymosis, lymphadenopathy. Platelet counts below 100,000/μL occurred in 84 patients (ET: 35; PV: 9; OMPD: 40), reduction below 50,000/μL occurred in 44 patients (ET: 7; PV: 6; OMPD: 31) while on Thromboreductin therapy. Thrombocytopenia promptly recovered upon discontinuation of Thromboreductin.

Hepatic System: Elevated liver enzymes were observed in 3 patients (ET: 2; OMPD: 1) during Thromboreductin therapy.

Musculoskeletal System: Arthralgia, myalgia, leg cramps.

Nervous System: Depression, somnolence, confusion, insomnia, nervousness, amnesia.

Nutritional Disorders: Dehydration.

Respiratory System: Rhinitis, epistaxis, respiratory disease, sinusitis, pneumonia, bronchitis, asthma.

Skin and Appendages System: Skin disease, alopecia.

Special Senses: Amblyopia, abnormal vision, tinnitus, visual field abnormality, diplopia.

Urogenital System: Dysuria, hematuria.

Renal abnormalities occurred in 15 patients (ET: 10; PV: 4; OMPD: 1). Six ET, 4 PV and 1 with OMPD experienced renal failure (approximately 1%) while on Thromboreductin treatment; in 4 cases, the renal failure was considered to be possibly related to Thromboreductin treatment. The remaining 11 were found to have pre-existing renal impairment. Doses ranged from 1.5-6.0 mg/day, with exposure periods of 2 to 12 months. No dose adjustment was required because of renal insufficiency. The adverse event profile for patients in three clinical trials on Thromboreductin therapy (in 5% or greater of 942 patients with myeloproliferative diseases) is shown in the following bar graph:

All Patients with Myeloproliferative Disease (N=942)

Postmarketing Reports

Interstitial lung diseases (including allergic alveolitis, eosinophilic pneumonia and interstitial pneumonitis) have been reported in patients who have taken Thromboreductin treatment in post-marketing reports

Thromboreductin contraindications

See also:
What is the most important information I should know about Thromboreductin?

Do not take Thromboreductin

• If you are allergic (hypersensitive) to Thromboreductin or any of the other ingredients of Thromboreductin. Check the ingredients of Thromboreductin listed in Section 6 of this leaflet. An allergic reaction may be recognised as a rash, itching, swollen face or lips, or shortness of breath.

• If you have moderate or severe liver problems.

• If you have moderate or severe kidney problems.

Take special care with Thromboreductin

Before treatment with Thromboreductin, tell your doctor

• If you have or think you might have a problem with your heart.

• If you have any problems with your liver or kidneys.

• If you are pregnant or breastfeeding.

• If you have been told by a doctor that you have an intolerance to some sugars.

Active ingredient matches for Thromboreductin:

Anagrelide in Austria, Bulgaria, Croatia (Hrvatska), Czech Republic, Hong Kong, Indonesia, Latvia, Lithuania, Malaysia, Poland, Romania, Serbia, Slovenia, South Africa, Switzerland, Thailand, Turkey.

Anagrelide HCl in Thailand.

Anagrelide hydrochloride in Malaysia.

Unit description / dosage (Manufacturer)Price, USD
Thromboreductin 0.5 mg x 100's
Thromboreductin 0.5 mg x 42's$ 218.86

List of Thromboreductin substitutes (brand and generic names):

Capsule; Oral; Anagrelide Hydrochloride Monohydrate 0.5 mg
Dom-anagrelide capsule 0.5 mg (Dominion Pharmacal (Canada))
Capsule; Oral; Anagrelide Hydrochloride 0.5 mg
Capsule; Oral; Anagrelide Hydrochloride 0.5 mg
Mylan-anagrelide capsule 0.5 mg (Mylan Pharmaceuticals Ulc (Canada))
Capsule; Oral; Anagrelide Hydrochloride Monohydrate 0.5 mg
PHL-anagrelide capsule 0.5 mg (Pharmel Inc (Canada))
Capsule; Oral; Anagrelide Hydrochloride Monohydrate 0.5 mg
PMS-anagrelide capsule 0.5 mg (Pharmascience Inc (Canada))
Capsule; Oral; Anagrelide Hydrochloride 0.5 mg
Capsule; Oral; Anagrelide Hydrochloride 0.5 mg
Sandoz Anagrelide capsule 0.5 mg (Sandoz Canada Incorporated (Canada))
Capsule; Oral; Anagrelide Hydrochloride 0.5 mg (Genesis)
Xagrid Capsule, hard 0.5 mg (Genesis)


  1. PubChem. "anagrelide". (accessed September 17, 2018).
  2. DrugBank. "anagrelide". (accessed September 17, 2018).
  3. MeSH. "Fibrinolytic Agents". (accessed September 17, 2018).


The results of a survey conducted on for Thromboreductin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Thromboreductin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet

Consumer reported price estimates

No survey data has been collected yet

2 consumers reported time for results

To what extent do I have to use Thromboreductin before I begin to see changes in my health conditions?
As part of the reports released by website users, it takes 1 month and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Thromboreductin. To get the time effectiveness of using Thromboreductin drug by other patients, please click here.
1 month1
> 3 month1

7 consumers reported age

> 602

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 15 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 All Rights Reserved